Cilnidipine is a dihydropyridine calcium channel blocker with action on both N- and L-type calcium channels used to treat hypertension. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995.
- Mechanism
- Curator reviewed · 1 reference
Cilnidipine acts on the L-type calcium channels of blood vessels by blocking the incoming calcium and suppressing the contraction of blood vessels, thereby reducing blood pressure. Cilnidipine also works on the N-type calcium channel located at the end of the sympathetic nerve, inhibiting the emission of norepinephrine and suppressing the increase in stress blood pressure.
- Primary indication
- Cilnidipine is indicated for the management of hypertension for end-organ protection.Curator reviewed · 1 structured indication
- Formula / weight
- C27H28N2O7 · 492.528 g/mol (avg)
Resolves to
KJEBULYHNRNJTE-DHZHZOJOSA-NSMILESCOCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Cilnidipine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account